Program
brexanolone
Also written as “SAGE-547”, “Brexanolone” and “LPCN 1154A”.
Its studies are mostly in Depression, Postpartum · Status Epilepticus · Tinnitus · Respiratory Distress Syndrome · Essential Tremor, led by 2 companies.
Drug pageBrexanolone: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Supernus Pharmaceuticalsits history only | 120 open or running | phase 4since Feb 14, 2020 | Jan 28, 2014 | none ahead |
| Lipocine | 21 open or running | phase 3since May 13, 2025 | May 13, 2025 | Aug 2027phase 3 · NCT07822321 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Lipocine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named brexanoloneINNProposed as its International Nonproprietary Name in WHO's List 117 · before, SAGE-547, LPCN 1154A
- May 13, 2025First study: phase 3 study in Depression, PostpartumFirst studyNCT06979544 · 90 enrolled · United States
- Sep 10, 2026Phase 3 study in Depression, PostpartumNCT07822321 · 120 planned · United States
Ahead
- Aug 2027Primary completion: phase 3 study in Depression, PostpartumNCT07822321
TargetBeta
“GABA-A receptor; anion channel positive allosteric modulator”ChEMBL 37, by rule
Other programs on the same 16 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Midazolamrule | Eli Lilly | phase 4 | 97 |
| ciprofolrule | Haisco Pharmaceutical Group | phase 4 | 36 |
| Alprazolamrule | Viatris | phase 4 | 35 |
| Diazepamrule | Acorda Therapeutics | phase 3 | 9 |
Studies
All 2 Lipocine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07822321Depression, Postpartum · United States | 3 | Recruiting | Aug 2027 | 120 |
| NCT06979544Depression, Postpartum · United States | 3 | Completed | Jan 16, 2026 | 90 |
How it is read
Names in the registry
- “SAGE-547”, 5 entries
- “Brexanolone”, 4 entries
- “LPCN 1154A”, 2 entries
- “SAGE-547 90 μg/kg/h”, 2 entries
- “SAGE-547 60 μg/kg/h”, 1 entry
Conditions, from the studies’ own filings
- Depression, Postpartum, 9 studies
- Status Epilepticus, 2 studies
- Tinnitus, 1 study
- Respiratory Distress Syndrome, 1 study
- Essential Tremor, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.